Excited to have this opinion piece on cannabis research published today. It's so hard to do placebo-controlled research with cannabis --but still a pretty great way to spend one's time. So much to learn
Regulatory barriers to conducting placebo-controlled studies of
#cannabis
leave clinicians and patients with little guidance. Exempting scientists from cannabis's Schedule I status is an expeditious solution to bridge the gap between evidence and practice
Very few medications decrease cannabis self-administration in daily cannabis smokers, but lorcaserin did!
@CarolineArout
@zivacooper
5HT‐2C agonist lorcaserin decreases cannabis self‐administration in daily cannabis smokers
I have tested the effects of a lot of medications for their potential to treat Cannabis Use Disorder and AEF0117 shows the most promise by far. This has been an exciting journey!
My husband’s public middle school students in the Bronx just WON a city-wide mock trial competition, beating both private and charter schools. With the seemingly endless barrage of racist, anti-immigrant, anti-Muslim, and anti-women messaging, this feels GOOD and I am proud!
Modafinil decreased smoked cocaine self-administration like no other medication we've ever tested ---under certain conditions. May help to explain why it sometimes works and sometimes does not in clinical trials
"...addiction as a brain disease does not deny the influence of social, environmental, developmental, or socioeconomic processes, but rather proposes that the brain is the underlying material substrate upon which those factors impinge and from which the responses originate"
Still so much to learn about this interaction! Cannabis Use and the Endocannabinoid System: A Clinical Perspective | American Journal of Psychiatry Thanks to
@CarolineArout
for many of these ideas.
Deeply touched to receive this award from the Center for Medicinal Cannabis Research
@UCSanDiego
. Being recognized by colleagues I respect so much is just a great feeling
@ColumbiaPsych
My New Year's resolution last year (1/1/20) was to get a study finished in 2015 published. I just submitted the revisions 1 hour ago......12/31/20. Ridiculous how long this took but I'm still so happy
#AcademicTwitter
Favorite thing about ACNP is learning exquisite science outside of my area of expertise. Presidential plenary on neurodevelopment is delivering exactly that.
#ACNP2020
Essential to free up scientific research NOW for placebo-controlled study of cannabis. Need to answer key questions: what indications, route of administration, cannabinoid ratios, dose, etc. Currently too little evidence and too much marketing
Conducting placebo-controlled studies on the effects of cannabis and cannabinoids on psychiatric symptoms is tricky but an important piece to the puzzle, especially given that anxiety is one of the most common reasons patients seek medical cannabis...happy to have contributed!
Third: We classify marijuana at the same level as heroin – and more serious than fentanyl. It makes no sense. I’m asking
@SecBecerra
and the Attorney General to initiate the process of reviewing how marijuana is scheduled under federal law.
New episode of AJP Audio with
@MegHaneyPhD
@ColumbiaPsych
discussing her overview article, “Cannabis Use and the Endocannabinoid System” as well as the legal status of cannabis research. Editor Ned Kalin also joins to discuss the January issue.
What is the best endpoint to use when treating Cannabis Use Disorder? Colleagues (and leaders in the field) address this important topic
@ColumbiaPsych
@DrugAlcoholDep
In
@DrugAlcoholDep
our
@ColumbiaPsych
research group reports on non-abstinent treatment outcomes for cannabis use disorder, reconsidering whether abstinence should be the primary outcome for cannabis use disorder clinical trials.
"As
@US_FDA
toils over how to regulate CBD, frustration builds" via
@NicholasFlorko
@statnews
cc
@jonathanstea
“There’s still much we don’t know — about the consequences of long-term use, about the risks to vulnerable populations, and lots more.”
High doses of oral CBD can exacerbate THC’s effects through inhibition of THC metabolism, leading to stronger drug effects. Cannabis users, clinicians, and regulators stakeholders must understand the potential risk of drug interactions.
Recruitment for our study on High CBD:low THC capsules for the treatment of chemotherapy- induced neuropathic pain began today at the
#SusanGKomenRace
. Grateful to have a table there!
#columbiapsychiatry
You are not ready for this line-up 😶
Check out the (current) list of speakers for
#EBPS2024
. Join us for our workshop:
"Novel pharmacotherapies to treat substance use disorders: From basic science to societal implications"
Registration March 20th
So sad. I was a big fan of Dr. Kreek as a scientist and person. In 2014, she invited me to give a talk at RU. As I was working on it, I got a call asking me where I was. I had the WRONG DAY. She covered for me as I raced across town and was only gracious about my GIANT screw-up.
We are sad to share that our beloved colleague Mary Jeanne Kreek has passed away. Her work not only yielded new treatments for addiction disorders, but also influenced societal attitudes toward them. She will be sorely missed.
👏🏽👏🏽👏🏽
@MegHaneyPhD
on medical cannabis -
@TIME
special edition:
“the drug absolutely has therapeutic potential, but it’s become a billion-dollar industry, and a lot of the discussion of it as medicine is being pushed by the industry”
⬆️honesty
⬇️ hype
A lot has been discussed about the effects
#cannabis
has on the human body and mind – but is it good or bad for you?
@MegHaneyPhD
, director of Columbia’s Cannabis Research Laboratory, discusses everything we currently know about cannabis.
#ColumbiaMed
With people increasingly using cannabinoids therapeutically, including for pain, we need to understand how outcomes may change with repeated cannabis use & upon abrupt abstinence. Super excited to be the focus of
@ColumbiaPsych
’s feature w/
@MegHaneyPhD
!
@UCLAResearch
hosts monthly events as part of our “Cannabis Conversations During COVID” series.
Very excited that
@MegHaneyPhD
is joining for our next event on October 29th 5 PT/ 8 ET. Stay tuned for RSVP link!
Thanks to
@MegHaneyPhD
for sharing results from a double-blind placebo-controlled study on cannabis impact on chemo-induced neuropathic pain this morning at
#ICRS2022GALWAY
& for pointing out that placebo-controlled studies are needed to fully understand the effects of cannabis!
Such a pleasure to speak with
@tekramos
about her research on subjective effects of acute cannabis intoxication and plasma levels of endocannabinoids at the
@ColumbiaPsych
Poster session!
I enjoyed reading the ‘data’ this company used to promote their nonsense: ‘100 out of 100 people lost weight!’ Counterculture to Counterintuitive: Cannabis to Help You Diet?
Psychiatry needs placebo-controlled cannabis trials. Thrilled to have had the chance to actually do one, thanks to support from
@MegHaneyPhD
and
@ColumbiaOCD
! Results have implications for OCD and anxiety treatment. Check out our latest paper here:
Glad to participate in this piece describing how studying cannabis/CBD is about 1 million times harder than just buying the stuff for yourself
#ColumbiaPsych
,
#CPDD19
"Columbia is a liberal, disgraceful institution" -- Trump to Sharyl Attkisson on Columbia University study that found 30,000 lives could've been saved had his federal government recommended social distancing measures just one week earlier
Our new paper in Addiction Biology is live!
OPEN ACCESS.
Brain imaging of cannabinoid type I (CB1) receptors in women with cannabis use disorder and male and female healthy controls
Feeling the pain after a long work week? Smoke pot…or not? We’re showing that repeated cannabis use results in analgesic tolerance, which reverses with abstinence…but you might also become more sensitive to pain when you stop using
#cannabis
!
#sciencecelebration
@ColumbiaPsych
Great to see this published! Preclinical data with cannabinoids for glioblastoma are exciting -- happy to see a promising placebo-controlled human study for this terrible disease
I started tearing up for lady Gaga, more for the swearing in of Kamala Harris, and haven’t stopped. It is like after the train wreck and you lose it as you realize you survived.
Always a good time hanging with my cannabis science peeps
@MegHaneyPhD
and Ryan Vandrey, this time as a trio of plenaries at the
#CCORC
meeting in Orlando
I am incredibly grateful for the education my son received
@RegisHighSchool
, and although I am happily married to Mr. James J. Donohue, I have never been ‘Mrs. James J. Donohue.’ What century is this again? 😂
Really enjoyed my time on 'Science Rules!' and recommend the podcast overall. Today it's cannabis but I've learned about a broad range of topics (from Neanderthals to concussions).
#ColumbiaPsych
@YalePsych
I am so terribly sad about this news. I admired Kathy deeply as a scientist but I also really liked her. She was so much fun to spend time with. It's a terrible loss and I'll miss her.
This humble, persistent, largely ignored bench scientist kind of saved the world. What a story.
Kati Kariko Helped Shield the World From the Coronavirus
Big news... and it only took 5 years to get here! Hope it will take less than 5 years for this decision to have a + impact on research...
DEA Finally Ready To End Federal Marijuana Research Monopoly, Agency Notifies Grower Applicants | Marijuana Moment
When based on associations observed in the population (ie, without control for confounders), claims made about the changes in risk for schizophrenia stemming from changing levels of cannabis use are very likely to be exaggerated and potentially substantially so.
Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia | Adolescent Medicine | JAMA Psychiatry | JAMA Network
So grateful for this thoughtful gift. Shout out to Loretta Finnegan and Ellen Geller for finding this beautiful vase from Garcia Art Glass studio in San Antonio. I will always treasure it.
#CPDD19
New review with some of my favorite people
@MegHaneyPhD
@HillardCece
@drdebah
@haleyv
on current state of endocannabinoid based therapeutics in the context of psychiatric illlness, with a focus on substance use disorders, trauma-related disorders and ASD.
Proud to have played a small role in this comprehensive and thoughtful review by
@tekramos
on rTMS as a potential treatment for Cannabis Use Disorder. Stay tuned!
Last, but certainly not least, we have an impactful review exploring the use of non-invasive rTMS as a treatment approach for Cannabis Use Disorder by Tonisha Kearney-Ramos and
@MegHaneyPhD
:
Need a break from the news? Tune in to catch
@UCLAResearch
's Cannabis Conversations During COVID with
@MegHaneyPhD
and her biggest fan: a 105 year old (and my grandmother) who agrees..... we need more
#cannabis
science!
Excited to share the results of our pilot trial of nabilone in adults with
#OCD
! We tested nabilone's acceptability/tolerability and preliminary efficacy alone and when paired with
#ERP
.
How is it still acceptable to address letters this way (especially if you are < 90 years old)? My husband’s name is Jim Donohue. I love him very much but I am absolutely not Mrs. Jim Donohue.
Godspeed with the bill to ease research restrictions on cannabis and CBD: "anecdotal evidence alone cannot be the basis for developing new medications. Research is subject to burdensome regulations which may inhibit research and medication development.”
So happy to have contributed to this important study showing robust neural value attributed to cannabis (real not hypothetical!) but not to a preferred food option. Decision-making by daily cannabis users doesn’t look so habitual here.
The photos from
#ccic2019
are in and we thought this was a good opportunity to celebrate and highlight some of the 🇨🇦 and 🇺🇸 boss women who spoke at our meeting and are driving research in the cannabis field.
My husband's 7th-grade students in the Bronx wrote this poem after January 6th, worried about their rep, AOC. Proud!
@Dream_Yard
,
@AOC
We Stand with AOC via
@YouTube
Like with 9/11, it is my sense that New Yorkers are being a bit gentler today-- strangers smiling slightly when you pass. Admittedly, the bar is pretty low🙂
Great work. I hated this narrative when I started behavioral studies in the 1980s. Pushed me to focus on maternal aggression just to get the girls in the game!
New paper from
@Datta_Lab
with a little help from yours truly, using MoSeq to show that female exploratory behavior in mice is in fact TWICE as stable as that in males, and that estrous cycle has only a negligible effect on behavioral variation.
We're hiring:
Looking for motivated postdocs interested in human
#cannabis
/
#cannabinoid
research in sunny LA!
Learn more about the UCLA Cannabis Research Initiative here:
Please RT!
Finished work a little early today, listened to a podcast while I stood in line, friendly volunteers keeping it socially distanced around the block
And at the Armory in Washington Heights, the volunteers applaud after your scan your ballot.
10/10 would recommend.
#VOTE
SESSION EXCEPTIONNELLE :
« Nouvelles données sur les inhibiteurs spécifiques de la signalisation du récepteur CB1 : une nouvelle piste thérapeutique pour les troubles liés au
#Cannabis
»
Modération :
@NicolasAuthier_
→ Pr
#PierVincenzoPIAZZA
→ Pr
@MegHaneyPhD
Please tell anyone you know in the NYC area who might be suffering from the consequences of breast cancer chemotherapy about this first-of-its-kind study! We are recruiting.
Good morning and Happy Sunday to everyone who loves the sight of awesome New Yorkers trolling trump with their hilarious “going out of business” sale at trump Tower! 🤣🤣🤣